SAG
EWTX icon

SageView Advisory Group’s Edgewise Therapeutics EWTX Stock Holding History

SageView Advisory Group’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$273 Buy
+11
New +$221 ﹤0.01% 2496

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

SageView Advisory Group's EWTX Position: Q4 2025 in Review

SageView Advisory Group opened a new position in Edgewise Therapeutics (EWTX) in Q4 2025: 11 shares worth $273. The stake represents ﹤0.01% of the portfolio and ranks #2496 among its holdings.

199 funds tracked by Wall St. Rank hold EWTX as of Q4 2025.

  • SageView Advisory Group held 11 shares of Edgewise Therapeutics worth $273 as of Q4 2025.
  • Edgewise Therapeutics was a new SageView Advisory Group position in Q4 2025.
  • Edgewise Therapeutics made up ﹤0.01% of SageView Advisory Group's portfolio in Q4 2025, its #2496 holding.
  • 199 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q4 2025.

Based on SageView Advisory Group's 13F filing for Q4 2025, filed 17 Feb 2026.